EcoR1 Capital’s Orexigen Therapeutics, Inc. OREX Stock Holding History

EcoR1 Capital’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-117,726	Closed	-$405K	–	47
2017 Q1	$405K	Buy	+117,726	New	+$465K	0.1%	31
2015 Q4	–	Sell	-93,796	Closed	-$1.98M	–	36
2015 Q3	$1.98M	Buy	+93,796	New	+$3.21M	0.9%	21

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $944M AUM 90.26% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EcoR1 Capital's OREX Position: Q2 2017 in Review

EcoR1 Capital sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2017, closing a stake of 117,726 shares — an estimated $405K sold.

EcoR1 Capital first reported a position in OREX in Q3 2015 and held it in 2 quarters. The position peaked at $1.98M in Q3 2015. 51 funds tracked by Wall St. Rank hold OREX as of Q2 2017.

EcoR1 Capital reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
EcoR1 Capital sold 117,726 Orexigen Therapeutics, Inc. shares in Q2 2017, an estimated $405K.
EcoR1 Capital first reported a position in Orexigen Therapeutics, Inc. in Q3 2015 and held it in 2 quarters.
EcoR1 Capital's Orexigen Therapeutics, Inc. position peaked at $1.98M in Q3 2015.
51 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2017.

Based on EcoR1 Capital's 13F filing for Q2 2017, filed 14 Aug 2017.